Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07157423
PHASE4

A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This study will look at how safe is the medicine eptacog alfa when used in women in India for stopping heavy bleeding after giving birth. If participants have heavy bleeding after giving birth then they will get the medicine eptacog alfa. This study will be conducted to get more knowledge on the safety of the medicine eptacog alfa use in these women. At first participants will receive one dose of medicine eptacog alfa. If the given dose is not helpful to stop the bleeding, participants will get one additional dose. The study will last for about 30-35 days.

Official title: Safety of Eptacog Alfa in Severe Postpartum Haemorrhage in India: A Phase IV Interventional Study

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2025-08-26

Completion Date

2027-03-26

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

DRUG

Eptacog alfa (NovoSeven)

Participants will receive single dose of intravenous bolus injection of eptacog alfa (NovoSeven)

Locations (8)

KLE Belgum

Belagavi, Karnataka, India

Calicut Medical College

Kozhikode, Kerala, India

Calicut Medical College

Kozhikode, Kerala, India

Seth GS Medical College & KEM Hospital

Mumbai, Maharashtra, India

All India Institute of Medical Sciences_New Dehli

New Delhi, National Capital Territory of Delhi, India

SMS Hospital

Jaipur, Rajasthan, India

KLE Belgum

Belagavi, India

Post Graduate Institute of Medical Education & Research_Chandigarh

Chandigarh, India